Portfolio Holdings Detail for ISIN IE00BYZK4776
Stock Name / Fund iShares Healthcare Innovation UCITS ETF USD (Acc)
Issuer Blackrock
Entity holding fund iShares IV Public Limited Company
Entity Type Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF Ticker DRDR(GBX) LSE
ETF Ticker 2B78(EUR) F
ETF Ticker 2B78.DE(EUR) CXE
ETF Ticker DRDR.LS(GBX) CXE
ETF Ticker HEAL.AS(EUR) CXE
ETF Ticker HEAL.LS(USD) CXE
ETF Ticker HEALz(USD) CXE
ETF Ticker HEAL(EUR) ETF Plus
ETF Ticker DRDR.L(GBP) LSE

Holdings detail for SRPT

Stock Name	Sarepta Therapeutics Inc
Ticker	SRPT(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US8036071004
LEI	549300IKDPIED8J8IG21

Show aggregate SRPT holdings

News associated with SRPT

Leerink Partners Boosts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $15.00: Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) had its price target raised by analysts at Leerink Partners from $12.00 to $15.00 in a report issued on Tuesday,Benzinga reports. The firm currently has a “market perform” rating on the biotechnology company’s stock. Leerink Partners’ price target would indicate a potential downside of 12.89% from the stock’s […] - 2025-09-11 03:04:49
After Hours Most Active for Aug 29, 2025 : ELAN, NVDA, GOOG, PPBI, SRPT, COLB, MSFT, SNAP, KMI, XOM, NEE, PFE: The NASDAQ 100 After Hours Indicator is down -7.17 to 23,408.25. The total After hours volume is currently 173,977,891 shares traded.The following are the most active stocks for the after hours session: Elanco Animal Health Incorporated (ELAN) is unchanged at $18.35, with 22,912 - 2025-08-29 17:29:12
HC Wainwright Reiterates “Sell” Rating for Sarepta Therapeutics (NASDAQ:SRPT): Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “sell” rating reiterated by equities research analysts at HC Wainwright in a report released on Monday,Benzinga reports. A number of other research firms have also issued reports on SRPT. Barclays raised shares of Sarepta Therapeutics from an “underweight” rating to an “equal weight” rating and […] - 2025-08-27 02:30:45
SCHK's Underlying Holdings Could Mean 11% Gain Potential: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-08-21 10:39:22
Sarepta Therapeutics (NASDAQ:SRPT) Given New $17.00 Price Target at Bank of America: Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its price objective lifted by Bank of America to $17.00 in a research note issued to investors on Wednesday,Benzinga reports. They currently have an underperform rating on the biotechnology company’s stock. Other equities analysts have also issued reports about the company. Baird R W lowered Sarepta Therapeutics from […] - 2025-08-21 04:58:48
Sarepta Therapeutics (NASDAQ:SRPT) Price Target Raised to $12.00: Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its price objective hoisted by Deutsche Bank Aktiengesellschaft to $12.00 in a research note released on Friday,Benzinga reports. Deutsche Bank Aktiengesellschaft currently has a sell rating on the biotechnology company’s stock. Other research analysts have also issued reports about the stock. TD Cowen lowered shares of Sarepta Therapeutics […] - 2025-08-18 03:06:45
Vanguard Group Inc. Decreases Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT): Vanguard Group Inc. lowered its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 0.6% in the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 9,032,613 shares of the biotechnology company’s stock after selling 52,843 shares during the quarter. Vanguard Group Inc. owned about 0.09% […] - 2025-08-14 04:37:10
Stocks Rally on Positive Tariff News ad Rate Cut Hopes: The S&P 500 Index ($SPX ) (SPY ) today is up +0.48%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.39%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.71%. September E-mini S&P futures (ESU25 ) are up +0.53%, and September E-mini Nasdaq futures... - 2025-08-07 18:57:35
Stocks Rally on Positive Tariff News ad Rate Cut Hopes: The S&P 500 Index ($SPX ) (SPY ) today is up +0.48%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.39%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.71%. September E-mini S&P futures (ESU25 ) are up +0.53%, and September E-mini Nasdaq futures... - 2025-08-07 13:11:34
Stocks Rally on Positive Tariff News ad Rate Cut Hopes: The S&P 500 Index ($SPX ) (SPY ) today is up +0.48%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.39%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.71%. September E-mini S&P futures (ESU25 ) are up +0.53%, and September E-mini Nasdaq futures... - 2025-08-07 12:48:17
Stocks Rally on Positive Tariff News ad Rate Cut Hopes: The S&P 500 Index ($SPX ) (SPY ) today is up +0.48%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.39%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.71%. September E-mini S&P futures (ESU25 ) are up +0.53%, and September E-mini Nasdaq futures... - 2025-08-07 12:41:53
Barclays Upgrades Sarepta Therapeutics (NASDAQ:SRPT) to “Equal Weight”: Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) was upgraded by analysts at Barclays from an “underweight” rating to an “equal weight” rating in a research report issued to clients and investors on Tuesday, MarketBeat.com reports. The firm currently has a $22.00 target price on the biotechnology company’s stock. Barclays‘s price objective indicates a potential upside […] - 2025-07-31 05:26:59
Sarepta Therapeutics (NASDAQ:SRPT) Stock Rating Upgraded by Barclays: Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) was upgraded by research analysts at Barclays from an “underweight” rating to an “equal weight” rating in a report released on Tuesday, MarketBeat Ratings reports. The brokerage presently has a $22.00 target price on the biotechnology company’s stock. Barclays‘s price target would indicate a potential upside of 35.38% […] - 2025-07-31 05:26:59
Sarepta Therapeutics (NASDAQ:SRPT) Upgraded to Equal Weight at Barclays: Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) was upgraded by stock analysts at Barclays from an “underweight” rating to an “equal weight” rating in a research note issued on Tuesday, Marketbeat reports. The brokerage presently has a $22.00 price target on the biotechnology company’s stock. Barclays‘s price objective points to a potential upside of 31.34% […] - 2025-07-31 05:26:59
BMO Capital Markets Forecasts Strong Price Appreciation for Sarepta Therapeutics (NASDAQ:SRPT) Stock: Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) had its price target hoisted by BMO Capital Markets from $25.00 to $50.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has a “market perform” rating on the biotechnology company’s stock. BMO Capital Markets’ price objective would indicate a potential upside of 198.51% from the stock’s […] - 2025-07-31 05:26:58
William Blair Reaffirms “Outperform” Rating for Sarepta Therapeutics (NASDAQ:SRPT): Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “outperform” rating reissued by investment analysts at William Blair in a research report issued on Tuesday,RTT News reports. Other equities analysts have also recently issued reports about the stock. Bank of America reaffirmed an “underperform” rating on shares of Sarepta Therapeutics in a report on […] - 2025-07-31 05:26:58
Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Expected to Rise, Morgan Stanley Analyst Says: Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) had its price objective hoisted by equities researchers at Morgan Stanley from $15.00 to $20.00 in a report released on Tuesday,Benzinga reports. The brokerage currently has an “equal weight” rating on the biotechnology company’s stock. Morgan Stanley’s price target suggests a potential upside of 19.40% from the stock’s […] - 2025-07-31 03:02:52
HC Wainwright Reaffirms Sell Rating for Sarepta Therapeutics (NASDAQ:SRPT): Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “sell” rating restated by analysts at HC Wainwright in a note issued to investors on Tuesday, MarketBeat.com reports. A number of other equities research analysts also recently commented on SRPT. Piper Sandler reduced their price objective on shares of Sarepta Therapeutics from $32.00 to $18.00 […] - 2025-07-31 03:02:51
Sarepta Therapeutics (NASDAQ:SRPT) Stock Rating Upgraded by JPMorgan Chase & Co.: Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) was upgraded by equities researchers at JPMorgan Chase & Co. from an “underweight” rating to a “neutral” rating in a research note issued to investors on Tuesday, Marketbeat.com reports. The brokerage currently has a $24.00 target price on the biotechnology company’s stock. JPMorgan Chase & Co.‘s price target […] - 2025-07-31 03:02:51
Stocks Retreat Ahead of Results from Wednesday's FOMC Meeting: The S&P 500 Index ($SPX ) (SPY ) Tuesday closed down -0.30%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.46%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.21%. September E-mini S&P futures (ESU25 ) fell -0.30%, and September E-mini Nasdaq futures (NQU25... - 2025-07-30 12:49:47
Stocks Retreat Ahead of Results from Wednesday's FOMC Meeting: The S&P 500 Index ($SPX ) (SPY ) Tuesday closed down -0.30%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.46%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.21%. September E-mini S&P futures (ESU25 ) fell -0.30%, and September E-mini Nasdaq futures (NQU25... - 2025-07-30 08:23:02
Sarepta Therapeutics (NASDAQ:SRPT) Earns “Underperform” Rating from Needham & Company LLC: Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “underperform” rating reaffirmed by Needham & Company LLC in a report issued on Monday,Benzinga reports. Several other equities analysts have also recently issued reports on SRPT. Scotiabank raised Sarepta Therapeutics from a “sector perform” rating to a “sector outperform” rating and set a $80.00 price […] - 2025-07-30 04:54:53
Barclays Downgrades Sarepta Therapeutics (NASDAQ:SRPT) to Strong Sell: Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) was downgraded by equities research analysts at Barclays from a “hold” rating to a “strong sell” rating in a report released on Monday, MarketBeat Ratings reports. Other research analysts have also recently issued research reports about the stock. HC Wainwright reaffirmed a “sell” rating on shares of Sarepta […] - 2025-07-30 04:54:51
Stocks Retreat Ahead of Results from Wednesday's FOMC Meeting: The S&P 500 Index ($SPX ) (SPY ) Tuesday closed down -0.30%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.46%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.21%. September E-mini S&P futures (ESU25 ) fell -0.30%, and September E-mini Nasdaq futures (NQU25... - 2025-07-30 03:41:41
Sarepta Therapeutics (NASDAQ:SRPT) Shares Gap Up Following Analyst Upgrade: Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report) shares gapped up before the market opened on Tuesday after Barclays upgraded the stock from an underweight rating to an equal weight rating. The stock had previously closed at $13.86, but opened at $18.23. Barclays now has a $22.00 price target on the stock. Sarepta Therapeutics shares […] - 2025-07-30 02:14:47
Strong Earnings and Trade Deal Optimism Bolster Stocks: The S&P 500 Index ($SPX ) (SPY ) today is up +0.21%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.02%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.56%. September E-mini S&P futures (ESU25 ) are up +0.15%, and September E-mini Nasdaq futures... - 2025-07-29 20:49:20
Stocks Slide in Afternoon Session: The S&P 500 Index ($SPX ) (SPY ) today is down -0.27%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.25%. After starting off the day stronger, the 3 major stock indxes are in the... - 2025-07-29 20:19:00
Stocks Supported by Strong Earnings and Trade Deal Optimism: The S&P 500 Index ($SPX ) (SPY ) today is up +0.05%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.25%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.25%. September E-mini S&P futures (ESU25 ) are up +0.03%, and September E-mini Nasdaq futures... - 2025-07-29 14:38:53
Stocks Supported by Strong Earnings and Trade Deal Optimism: The S&P 500 Index ($SPX ) (SPY ) today is up +0.05%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.25%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.25%. September E-mini S&P futures (ESU25 ) are up +0.03%, and September E-mini Nasdaq futures... - 2025-07-29 14:12:43
Strong Earnings and Trade Deal Optimism Bolster Stocks: The S&P 500 Index ($SPX ) (SPY ) today is up +0.21%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.02%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.56%. September E-mini S&P futures (ESU25 ) are up +0.15%, and September E-mini Nasdaq futures... - 2025-07-29 14:12:42

iShares Healthcare Innovation UCITS ETF USD (Acc) SRPT holdings

Date	Number of SRPT Shares Held	Base Market Value of SRPT Shares	Local Market Value of SRPT Shares	Change in SRPT Base Value	Current Price per SRPT Share Held	Previous Price per SRPT Share Held
2025-11-11 (Tuesday)	119,121	USD 2,141,796	USD 2,141,796	USD 84,576	USD 17.98	USD 17.27
2025-11-10 (Monday)	119,121	USD 2,057,220	USD 2,057,220	USD -42,883	USD 17.27	USD 17.63
2025-11-07 (Friday)	119,121	USD 2,100,103	USD 2,100,103	USD -1,191	USD 17.63	USD 17.64
2025-11-06 (Thursday)	119,121	USD 2,101,294	USD 2,101,294	USD -122,695	USD 17.64	USD 18.67
2025-11-05 (Wednesday)	119,121	USD 2,223,989	USD 2,223,989	USD 294,229	USD 18.67	USD 16.2
2025-11-04 (Tuesday)	119,121	USD 1,929,760	USD 1,929,760	USD -982,748	USD 16.2	USD 24.45
2025-11-03 (Monday)	119,121	USD 2,912,508	USD 2,912,508	USD 52,413	USD 24.45	USD 24.01
2025-10-31 (Friday)	119,121	USD 2,860,095	USD 2,860,095	USD 90,532	USD 24.01	USD 23.25
2025-10-30 (Thursday)	119,121	USD 2,769,563	USD 2,769,563	USD -23,824	USD 23.25	USD 23.45
2025-10-29 (Wednesday)	119,121	USD 2,793,387	USD 2,793,387	USD -91,724	USD 23.45	USD 24.22
2025-10-28 (Tuesday)	119,121	USD 2,885,111	USD 2,885,111	USD 85,767	USD 24.22	USD 23.5
2025-10-27 (Monday)	119,121	USD 2,799,344	USD 2,799,344	USD 82,194	USD 23.5	USD 22.81

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of SRPT by Blackrock for IE00BYZK4776

Show aggregate share trades of SRPT

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-10-24 SELL -1,012 22.810 23.430 23.368 USD -23,648 68.63 Profit of 45,807 on sale
2025-09-11 BUY 509 17.910 17.950 17.946 USD 9,135 74.55
2025-07-08 SELL -506 19.030 19.360 19.327 USD -9,779 79.91 Profit of 30,654 on sale
2025-06-24 SELL -509 18.980 19.430 19.385 USD -9,867 83.93 Profit of 32,854 on sale
2025-06-23 SELL -509 18.870 19.760 19.671 USD -10,013 84.40 Profit of 32,948 on sale
2025-06-20 BUY 4,653 20.080 20.880 20.800 USD 96,782 84.87
2025-06-11 SELL -487 37.810 39.640 39.457 USD -19,216 87.94 Profit of 23,611 on sale
2025-05-30 SELL -487 37.600 38.150 38.095 USD -18,552 91.13 Profit of 25,826 on sale
2025-05-21 BUY 487 40.050 44.140 43.731 USD 21,297 94.34
2025-05-14 SELL -2,922 35.740 37.420 37.252 USD -108,850 96.39 Profit of 172,809 on sale
2025-04-30 SELL -486 62.400 62.510 62.499 USD -30,375 101.17 Profit of 18,795 on sale
2025-04-28 SELL -486 61.510 62.470 62.374 USD -30,314 101.98 Profit of 19,249 on sale
2025-04-25 SELL -486 60.440 61.920 61.772 USD -30,021 102.40 Profit of 19,747 on sale
2025-04-11 SELL -2,922 51.030 51.800 51.723 USD -151,135 106.53 Profit of 160,158 on sale
2025-04-08 SELL -1,461 49.300 55.360 54.754 USD -79,996 108.42 Profit of 78,411 on sale
2025-04-07 BUY 1,386 52.400 55.170 54.893 USD 76,082 109.07
2025-03-31 SELL -956 63.820 67.470 67.105 USD -64,152 111.44 Profit of 42,381 on sale
2025-03-21 SELL -954 74.100 75.500 75.360 USD -71,893 114.46 Profit of 37,298 on sale
2025-03-12 SELL -478 99.770 102.400 102.137 USD -48,821 117.03 Profit of 7,118 on sale
2025-02-28 SELL -478 106.750 108.480 108.307 USD -51,771 118.81 Profit of 5,021 on sale
2025-02-25 BUY 478 106.950 107.110 107.094 USD 51,191 119.49
2025-02-20 SELL -478 108.410 109.830 109.688 USD -52,431 120.19 Profit of 5,020 on sale
2025-02-19 BUY 956 107.120 107.460 107.426 USD 102,699 120.43
2025-02-18 BUY 478 105.350 106.100 106.025 USD 50,680 120.72
2024-12-30 BUY 902 121.190 121.630 121.586 USD 109,671 124.56
2024-12-06 SELL -470 128.170 129.060 128.971 USD -60,616 124.22 Loss of -2,231 on sale
2024-12-04 SELL -470 126.530 127.960 127.817 USD -60,074 124.07 Loss of -1,762 on sale
2024-12-03 SELL -940 126.010 128.490 128.242 USD -120,547 124.00 Loss of -3,991 on sale
2024-11-22 BUY 751 114.230 114.830 114.770 USD 86,192 122.57
2024-11-21 SELL -468 110.500 111.780 111.652 USD -52,253 123.20 Profit of 5,406 on sale
2024-11-20 SELL -466 110.860 111.380 111.328 USD -51,879 123.89 Profit of 5,853 on sale
2024-11-19 BUY 357 106.620 106.990 106.953 USD 38,182 124.90
2024-11-18 SELL -1,856 104.670 105.980 105.849 USD -196,456 126.17 Profit of 37,715 on sale
2024-11-12 SELL -464 114.320 118.730 118.289 USD -54,886 126.96 Profit of 4,023 on sale
2024-11-07 SELL -464 120.420 133.000 131.742 USD -61,128 127.87 Loss of -1,795 on sale
2024-11-05 SELL -928 125.010 125.250 125.226 USD -116,210 128.13 Profit of 2,691 on sale
2024-10-28 SELL -464 130.260 132.800 132.546 USD -61,501 129.75 Loss of -1,295 on sale
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-10-24	SELL	-1,012	22.810	23.430	23.368	USD -23,648	68.63 Profit of 45,807 on sale
2025-09-11	BUY	509	17.910	17.950	17.946	USD 9,135	74.55
2025-07-08	SELL	-506	19.030	19.360	19.327	USD -9,779	79.91 Profit of 30,654 on sale
2025-06-24	SELL	-509	18.980	19.430	19.385	USD -9,867	83.93 Profit of 32,854 on sale
2025-06-23	SELL	-509	18.870	19.760	19.671	USD -10,013	84.40 Profit of 32,948 on sale
2025-06-20	BUY	4,653	20.080	20.880	20.800	USD 96,782	84.87
2025-06-11	SELL	-487	37.810	39.640	39.457	USD -19,216	87.94 Profit of 23,611 on sale
2025-05-30	SELL	-487	37.600	38.150	38.095	USD -18,552	91.13 Profit of 25,826 on sale
2025-05-21	BUY	487	40.050	44.140	43.731	USD 21,297	94.34
2025-05-14	SELL	-2,922	35.740	37.420	37.252	USD -108,850	96.39 Profit of 172,809 on sale
2025-04-30	SELL	-486	62.400	62.510	62.499	USD -30,375	101.17 Profit of 18,795 on sale
2025-04-28	SELL	-486	61.510	62.470	62.374	USD -30,314	101.98 Profit of 19,249 on sale
2025-04-25	SELL	-486	60.440	61.920	61.772	USD -30,021	102.40 Profit of 19,747 on sale
2025-04-11	SELL	-2,922	51.030	51.800	51.723	USD -151,135	106.53 Profit of 160,158 on sale
2025-04-08	SELL	-1,461	49.300	55.360	54.754	USD -79,996	108.42 Profit of 78,411 on sale
2025-04-07	BUY	1,386	52.400	55.170	54.893	USD 76,082	109.07
2025-03-31	SELL	-956	63.820	67.470	67.105	USD -64,152	111.44 Profit of 42,381 on sale
2025-03-21	SELL	-954	74.100	75.500	75.360	USD -71,893	114.46 Profit of 37,298 on sale
2025-03-12	SELL	-478	99.770	102.400	102.137	USD -48,821	117.03 Profit of 7,118 on sale
2025-02-28	SELL	-478	106.750	108.480	108.307	USD -51,771	118.81 Profit of 5,021 on sale
2025-02-25	BUY	478	106.950	107.110	107.094	USD 51,191	119.49
2025-02-20	SELL	-478	108.410	109.830	109.688	USD -52,431	120.19 Profit of 5,020 on sale
2025-02-19	BUY	956	107.120	107.460	107.426	USD 102,699	120.43
2025-02-18	BUY	478	105.350	106.100	106.025	USD 50,680	120.72
2024-12-30	BUY	902	121.190	121.630	121.586	USD 109,671	124.56
2024-12-06	SELL	-470	128.170	129.060	128.971	USD -60,616	124.22 Loss of -2,231 on sale
2024-12-04	SELL	-470	126.530	127.960	127.817	USD -60,074	124.07 Loss of -1,762 on sale
2024-12-03	SELL	-940	126.010	128.490	128.242	USD -120,547	124.00 Loss of -3,991 on sale
2024-11-22	BUY	751	114.230	114.830	114.770	USD 86,192	122.57
2024-11-21	SELL	-468	110.500	111.780	111.652	USD -52,253	123.20 Profit of 5,406 on sale
2024-11-20	SELL	-466	110.860	111.380	111.328	USD -51,879	123.89 Profit of 5,853 on sale
2024-11-19	BUY	357	106.620	106.990	106.953	USD 38,182	124.90
2024-11-18	SELL	-1,856	104.670	105.980	105.849	USD -196,456	126.17 Profit of 37,715 on sale
2024-11-12	SELL	-464	114.320	118.730	118.289	USD -54,886	126.96 Profit of 4,023 on sale
2024-11-07	SELL	-464	120.420	133.000	131.742	USD -61,128	127.87 Loss of -1,795 on sale
2024-11-05	SELL	-928	125.010	125.250	125.226	USD -116,210	128.13 Profit of 2,691 on sale
2024-10-28	SELL	-464	130.260	132.800	132.546	USD -61,501	129.75 Loss of -1,295 on sale

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of SRPT

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	983,569	11,582	2,229,356	44.1%
2025-09-18	1,090,475	13,256	2,892,181	37.7%
2025-09-17	1,084,432	12,646	2,880,085	37.7%
2025-09-16	894,021	24,794	2,572,516	34.8%
2025-09-15	965,390	17,413	1,966,976	49.1%
2025-09-12	653,958	4,450	1,496,524	43.7%
2025-09-11	1,072,912	20,779	2,821,710	38.0%
2025-09-10	1,151,235	26,938	2,519,731	45.7%
2025-09-09	912,384	5,700	1,971,308	46.3%
2025-09-08	1,691,086	14,236	3,124,457	54.1%
2025-09-05	983,688	32,929	2,352,178	41.8%
2025-09-04	914,125	4,094	1,995,501	45.8%
2025-09-03	1,510,137	28,081	3,442,477	43.9%
2025-09-02	1,295,420	1,742	2,645,873	49.0%
2025-08-29	1,216,368	8,598	2,467,992	49.3%
2025-08-28	1,059,025	4,645	2,463,626	43.0%
2025-08-27	1,514,636	213	2,902,512	52.2%
2025-08-26	1,565,998	49,895	3,527,435	44.4%
2025-08-25	2,838,958	5,229	6,270,840	45.3%
2025-08-22	1,981,782	31,841	4,688,703	42.3%
2025-08-21	4,086,130	90,917	7,046,331	58.0%
2025-08-20	1,278,705	4,510	2,928,741	43.7%
2025-08-19	876,314	1,494	2,229,424	39.3%
2025-08-18	1,204,430	3,010	2,779,040	43.3%
2025-08-15	1,705,867	9,186	4,100,040	41.6%
2025-08-14	1,349,441	835	3,381,579	39.9%
2025-08-13	1,545,265	20,760	5,282,331	29.3%
2025-08-12	1,305,838	2,507	3,231,125	40.4%
2025-08-11	2,168,673	9,152	5,077,985	42.7%
2025-08-08	2,133,503	14,932	4,694,284	45.4%
2025-08-07	3,771,974	42,479	7,573,979	49.8%
2025-08-06	2,783,503	4,476	5,375,055	51.8%
2025-08-05	1,594,846	676	3,432,445	46.5%
2025-08-04	4,127,057	3,778	7,480,149	55.2%
2025-08-01	2,097,751	4,035	4,221,318	49.7%
2025-07-31	3,263,532	32,143	7,100,489	46.0%
2025-07-30	8,885,536	12,372	18,507,337	48.0%
2025-07-29	17,694,154	67,608	30,461,995	58.1%
2025-07-28	4,761,652	590,396	9,578,710	49.7%
2025-07-25	2,445,819	120,878	5,876,922	41.6%
2025-07-24	9,985,202	652,750	20,571,463	48.5%
2025-07-23	1,525,839	5,307	4,030,266	37.9%
2025-07-22	4,478,481	383,133	10,024,476	44.7%
2025-07-21	3,426,188	78,320	9,225,506	37.1%
2025-07-18	11,983,277	545,936	29,286,071	40.9%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares Healthcare Innovation UCITS ETF USD (Acc)
Issuer	Blackrock
Entity holding fund	iShares IV Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300ZP07LMR36K1T02
ETF Ticker	DRDR(GBX) LSE
ETF Ticker	2B78(EUR) F
ETF Ticker	2B78.DE(EUR) CXE
ETF Ticker	DRDR.LS(GBX) CXE
ETF Ticker	HEAL.AS(EUR) CXE
ETF Ticker	HEAL.LS(USD) CXE
ETF Ticker	HEALz(USD) CXE
ETF Ticker	HEAL(EUR) ETF Plus
ETF Ticker	DRDR.L(GBP) LSE